Sorrento Therapeutics Inc (NASDAQ:SRNE) announced the pricing of an underwritten public offering of 4,765,000 shares of common stock at a public offering price of $5.25 per share. The gross proceeds to Sorrento from this offering are expected to be approximately $25,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. Sorrento Therapeutics Inc (NASDAQ:SRNE) weekly performance is -32.85%. On last trading day company shares ended up $5.11. Analysts mean target price for the company is $24.00. Sorrento Therapeutics Inc (NASDAQ:SRNE) distance from 50-day simple moving average (SMA50) is -55.15%.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. Currently t 7 analysts that rate Celldex Therapeutics a buy, no analysts rate it a sell, and none rate it a hold. Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares fell -10.93% in last trading session and ended the day on $14.02. CLDX return on assets is -34.40%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) quarterly performance is -48.93%.
On MAY 8, 2014 Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), today announced financial and operational results for the first quarter ended March 31, 2014. Total revenues for the first quarter of 2014 were $9.1 million, compared to $8.1 million for the first quarter of 2013. First quarter 2014 revenues included $1.7 million in Fanapt® royalties received from Novartis as compared to royalties of $1.5 million for the first quarter of 2013. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares moved down -6.01% in last trading session and was closed at $9.86, while trading in range of $9.55 – $10.48. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) year to date (YTD) performance is -20.55%.
On MAY 1, 2014 Oncothyreon Inc. (NASDAQ: ONTY) reported financial results for the first quarter ended March 31, 2014. Loss from operations was $7.2 million for the first quarter ended March 31, 2014 compared with $8.0 million for the first quarter ended March 31, 2013. The decrease in loss from operations was primarily due to a $1.0 million decrease in research and development expenses for the first quarter ended March 31, 2014 compared to the first quarter ended March 31, 2013, which was partly offset by a slight increase in general and administrative expenses. Oncothyreon Inc (USA) (NASDAQ:ONTY) ended the last trading day at $2.65. Company weekly volatility is calculated as 7.14% and price to cash ratio as 3.12. Oncothyreon Inc (USA) (NASDAQ:ONTY) showed a positive weekly performance of 0.76%
Wedbush decreased their target price on shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) in a research report issued on Friday. Wedbush’s price target would suggest a potential downside of the company’s current price. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) weekly performance is 5.93%. On last trading day company shares ended up $9.11. Analysts mean target price for the company is $18.67. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) distance from 50-day simple moving average (SMA50) is -19.34%.